S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Ebix Launches AI-Driven Platform to Automate Medical Coding

JOHNS CREEK, Ga. — Ebix is rolling out its new A.D.A.M. Medical Coding Platform to automate the mapping of health content to industry standards like ICD-10 and LOINC. By integrating AI-supported workflows, the company aims to accelerate the delivery of clinical educational materials while maintaining its physician-led review process.

Ebix Launches AI-Driven Platform to Automate Medical Coding
Photo: Bio & News

The platform processes thousands of articles daily, structuring data for direct integration into electronic health records and patient portals. Beyond coding, Ebix has introduced AI-powered media tools capable of converting singular educational programs into varied formats, including video, audio, and transcripts. This upgrade provides physicians across 25 specialties with greater flexibility in how they access accredited medical information.

Chief Executive Officer Gagan Sethi expects these investments to bolster revenue growth and improve operating margins by streamlining production. Mary Beth Titsworth, Vice President of Health Content, emphasized that these automated efficiencies are designed to complement, rather than replace, clinical oversight. The company plans to leverage these capabilities to expand its content licensing footprint among health systems, payers, and digital health providers in both the United States and international markets where LOINC and ICD standards are utilized.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!